Physician profile
Ranjit Cheriyan
NPI 1851487383
$4,413.74
in general payments reported to CMS, 2019-2025
25 companies · $674 in 2025
The $674 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,225 · 2020: $129 · 2021: $572 · 2022: $482 · 2023: $727 · 2024: $606 · 2025: $674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,956 · Education: $49.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,956.31 |
| Education | $49.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $1,225.09 | 2020-2025 | Acthar |
| Ani Pharmaceuticals, INC. | $333.88 | 2022-2025 | Purified Cortrophin Gel |
| Mallinckrodt Enterprises LLC | $326.42 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $321.40 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $305.76 | 2019-2025 | |
| Ardelyx, INC. | $201.41 | 2024-2025 | Xphozah 30 Mg |
| Astrazeneca Pharmaceuticals LP | $179.90 | 2019-2023 | Farxiga |
| Vifor Pharma, INC. | $158.84 | 2019-2025 | Veltassa |
| Teva Pharmaceuticals USA, INC. | $138.60 | 2019 | |
| Travere Therapeutics, INC. | $135.43 | 2023-2025 | |
| Recor Medical INC | $133.88 | 2025 | Paradise Ultrasound Renal Denervation System |
| Amgen INC. | $128.23 | 2019 | |
| Antares Pharma, INC. | $125.00 | 2022 | |
| Akebia Therapeutics INC | $123.47 | 2019-2024 | Vafseo |
| Opko Pharmaceuticals, LLC | $76.30 | 2019-2025 | Rayaldee |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $75.76 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $74.48 | 2025 | |
| Horizon Therapeutics Plc | $73.83 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $69.46 | 2019-2020 | |
| Amarin Pharma, INC. | $59.12 | 2019-2021 | |
| Calliditas Therapeutics US INC. | $47.43 | 2024-2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $43.86 | 2019-2022 | |
| Novo Nordisk INC | $27.03 | 2025 | Rybelsus, Ozempic |
| Alexion Pharmaceuticals, INC. | $15.68 | 2021 | |
| Biomerieux INC | $13.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ranjit Cheriyan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.